Neurologic complications associated with the Zika virus in brazilian adults


Authors: da Silva IRF, Frontera JA, Bispo de Filippis AM, Nascimento OJMD

Published in: JAMA Neurol.2017;74(10):1190-1198

Importance  There are no prospective cohort studies assessing the incidence and spectrum of neurologic manifestations secondary to Zika virus (ZIKV) infection in adults.

Objective  To evaluate the rates of acute ZIKV infection among patients hospitalized with Guillain-Barré syndrome (GBS),

Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum


Authors: Bosch I, de Puig H, Hiley M, et al.

Published in: Sci Transl Med. 2017 Sep 27;9(409)

Abstract The recent Zika virus (ZIKV) outbreak demonstrates that cost-effective clinical diagnostics are urgently needed to detect and distinguish viral infections to improve patient care. Unlike dengue virus (DENV), ZIKV infections during pregnancy correlate with severe birth defects,

Structural investigation of C6/36 and Vero cell cultures infected with a Brazilian Zika virus


Authors: Barreto-Vieira DF, Jacome FC, da Silva MAN, et al.

Published in: PLoS One. 2017;12(9):e0184397

Abstract Zika virus (ZIKV) is a member of the flavivirus genus, and its genome is approximately 10.8 kilobases of positive-strand RNA enclosed in a capsid and surrounded by a membrane. Studies on the replication dynamics of ZIKV are scarce,

Antibody-based assay discriminates Zika virus infection from other flaviviruses


Authors: Balmaseda A, Stettler K, Medialdea-Carrera R, et al.

Published in: Proc Natl Acad Sci U S A. 2017;114(31):8384-8389

Abstract Zika virus (ZIKV) is a mosquito-borne flavivirus that emerged recently as a global health threat, causing a pandemic in the Americas. ZIKV infection mostly causes mild disease, but is linked to devastating congenital birth defects and Guillain-Barré syndrome in adults.

Accuracy of Zika virus disease case definition during simultaneous Dengue and Chikungunya epidemics


Authors: Braga JU, Bressan C, Dalvi APR, et al.

Published in: PLoS One.2017;12(6):e0179725. 

Background Zika is a new disease in the American continent and its surveillance is of utmost importance, especially because of its ability to cause neurological manifestations as Guillain-Barrésyndrome and serious congenital malformations through vertical transmission. The detection of suspected cases by the surveillance system depends on the case definition adopted.

Zika virus infection–associated acute transient polyneuritis


Authors: Nascimento OJM, Frontera JA, Amitrano DA, Bispo de Filippis AM, Da Silva IRF; RIO-GBS-ZIKV Research Group

Published in: Neurology 2017;88(24):2330-2332

Abstract Zika virus (ZIKV) has been associated with various neurologic complications in adults, including Guillain-Barré syndrome (GBS), transverse myelitis, meningoencephalitis, and ophthalmologic manifestations. Though some of these syndromes may be due to a postinfectious (molecular mimicry) mechanism,

Factors associated with time to virological response in children with perinatal HIV in Europe and Thailand initiating antiretroviral theraphy (ART) very early in infancy


Authors: Palma P, Chan M, Goodall R, Judd A, Gibb D, Babiker A, Rojo P.

Published: 35th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), May 23rd-27th May, 2017, Madrid

Background A major obstacle to curing HIV infection is persistence of virus as integrated proviral DNA in long-lived cells even after many years on ART.

B-cell responses in early treated long term viral suppressed seroneg HIV infected children


Authors: Palma P, Zangari P, Cotugno N, Rocca S, Nastouli E, McCoy LE, Ferns RB, Pahwa S, Rossi P

Published: 24th Conference on Retroviruses and Opportunistic Infections, February 13th – 16th, 2017, Seattle. P_1975.

Background It is still unknown whether the paucity of HIV-specific immune responses in early-treated (treated within 6 months of age; ET) HIV-infected children may represent a limitation or an advantage in the perspective of immune therapeutic studies.

Substantially lower rilpivirine plasma concentrations during pregnancy


Authors: Colbers A, Schalkwijk S, Konopnicki D, Gingelmaier A, Lambert J, van der Ende I, Moltó J, Burger D.

Published: 24th Conference on Retroviruses and Opportunistic Infections, February 13th – 16th, 2017 – Seattle. Abstract number 754.

“Not Taking it Will Just be Like a Sin”: Young People Living with HIV and the Stigmatization of Less-Than-Perfect Adherence to Antiretroviral Therapy


Authors: Bernays S, Paparini S, Seeley J, Rhodes T.

Published in: Med Anthropol. 2017;36(5):485-499.

Abstract: Global health priorities are being set to address questions on adherence to HIV antiretroviral therapy in adolescence. Few studies have explored young people’s perspectives on the complex host of social and relational challenges they face in dealing with their treatment in secret and their condition in silence.

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents – a multiregion analysis from Southern Africa, West Africa, and Europe


Authors: Schomaker M, Leroy V, Wolfs T, et al. On behalf of theIeDEA West and Southern Africa regional collaborations and COHERE in EuroCoord.

Published in: Int J Epidemiol. 2017;46(2):453-465.

Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents.

Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients,

Chronic Hepatites C in children in the Russian federation: a multicenter study


Authors: Volynets G, Skyortsowa TA, Ptapov AS, et al.

Published in: EASL, 19th – 23rd April 2017, Amsterdam


Co-infection with HIV and HCV in 229 children and young adults living in Europe


Authors: Thorne C, Turkova A, Indolfi G, Venturini E, Giaquinto C

Published in: AIDS. 2017;31(1):127-135.

Objective To characterize children, adolescents and young adults infected with HIV/hepatitis C virus (HCV) vertically or before age of 18 years and living in Europe regarding mode of acquisition, HCV genotype, clinical status and treatment.

Design Retrospective,

Hepatitis C Co-Infection and CD4+ T Cell Recovery in HIV-Infected Children Receiving Anti-Retroviral Therapy.


Authors: Majekodunmi AO, Thorne C, Malyuta R, et al.

Published in: Pediatr Infect Dis J. 2017;36(5):e123-e129

Background The effect of hepatitis C virus (HCV) coinfection on CD4 T cell recovery in treated HIV-infected children is poorly understood.

Objective To compare CD4 T cell recovery in HIV/HCV coinfected children with recovery in HIV monoinfected children.

The Challenge of Treating Children with Hepatitis C Virus Infection


Authors: Indolfi G, Thorne C, El-Sayed MH, Giaquinto C, Gonzalez-Peralta RP.

Published in: J Pediatr Gastroenterol Nutr. 2017;64(6):851-854

Abstract The development of oral hepatitis C virus (HCV) direct-acting antivirals (DAAs) has revolutionized the therapeutic field. Nowadays, multiple safe and highly effective antiviral regimens are commercially available to treat adults with hepatitis C infection.

Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy


Authors: Adedeji O MajekodunmiClaire ThorneRuslan MalyutaAlla VolokhaRobin E CallardNigel J KleinJoanna LewisEuropean Paediatric HIV/HCV Co-infection Study group in the European Pregnancy and Paediatric HIV Cohort Collaboration and the Ukraine Paediatric HIV Cohort Study in EuroCoord

Published in: Pediatr Infect Dis J.

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy


Authors: Colbers A, Best B, Schalkwijk S, et al. PANNA Network and the IMPAACT 1026 Study Team.

Published in: Clin Pharmacokinet. 2016;55(3):381-96

Abstract Pregnant women are usually excluded from clinical trials. Physiologically based pharmacokinetic (PBPK) modelling may provide a method to predict pharmacokinetics in pregnant women, without the need to perform extensive in vivo clinical trials.

Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates


Authors: Ramos-Martin R , Johnson A, Livermore J, et al.

Published in: J Antimicrob Ther 2016;71(4):992-1002

Prevalence of depressive symptoms in pregnant and postnatal HIV-positive women in Ukraine: a cross-sectional survey


Authors: Bailey H, Malyuta R, Townsend C, Cortina Borja M, Thorne C for the Ukraine European Collaborative Study in EuroCoord.

Published in: Reprod Health. 2016;22(3):13-27.

Background Perinatal depression among HIV-positive women has negative implications for HIV-related and other maternal and infant outcomes. The aim of this study was to investigate the burden and correlates of perinatal depression among HIV-positive women in Ukraine,

Zika virus: what have we learned?


Authors: Safadi MA

Published in: Amer J Perinatol.2016; 33(11): 1029-1031

Abstract Zika virus (ZIKV) is an emerging arthropod-borne, enveloped RNA virus of the Flaviviridae family, which belongs to the genus Flavivirus, related to dengue, yellow fever, Japanese encephalitis, and West Nile viruses. Two major lineages, African and Asian, have been identified through phylogenetic analyses.

Outcome of dengue in hospitalized jamaican children


Authors: Davidson T., Vickers I., Christie CD

Published in: West Indian Med J 2016;65(3);442-449

Background Dengue fever is hyper-endemic in Jamaica with exponential rates of infection in successive outbreaks. The absence of local data and the potential for massive outbreaks in a country where a third of the population are children formed the basis for this study.

Chikungunya in Jamaica – public health effects and clinical features in children


Authors: Christie CD, Melbourne-Chambers R, Ennevor J, et al.

Published in: West Indian Med J 2016;65(3);431-437

Background Chikungunya virus entered the Caribbean for the first time in 2013 and Jamaica experienced its maiden epidemic with Chikungunya Fever in 2014. We aimed to describe the public health effects and describe the clinical features in children and adolescents in Jamaica.

Emergence of Zika virus epidemic and the national response in Jamaica


Authors: Webster-Kerr K, Christie CDC, Grant A, et al.

Published in: West Indian Med J. 2016;65(1):243-249

Background Jamaica, along with the Americas, experienced major epidemics of arboviral diseases transmitted by the Aedes aegypti mosquito in recent years. These include dengue fever in 2012, chikungunya fever in 2014 and Zika virus infection (ZIKV) in 2016. We present the emergence of the ZIKV epidemic in Jamaica and outline the national response.

Prolonged shedding of Zika virus associated with congenital infection


Authors: Oliveira DB, Almeida FJ, Durigon EL, et al.

Published in: N Engl J Med. 2016. 22;375(12):1202-4

The presence of Zika virus (ZIKV) infection has been associated with microcephaly in multiple studies, although little is known about ZIKV shedding in congenitally infected infants. We report a case of a newborn who had continued viremia with ZIKV for at least 67 days after birth.

Unravelling the paediatric and perinatal Zika virus epidemic through population-based research


Authors: Christie CD, Giaquinto C

Published in: West Indian Med J.2016;65(1):239-242

Abstract Zika virus epidemic now involves 72 countries, worldwide. Transmission is multimodal through mosquito bites and blood and body fluids. Zika virus causes Guillain Barre Syndrome syndrome and pregnancy complications including perinatal microcephaly. Diagnosis is complicated by subclinical infection in 80%,

Zika virus infection in pregnant women in Barcelona, Spain


Authors: Bocanegra C, Sulleiro E, Soriano-Arandes A, et al.

Published in: Clin Microbiol Infect. 2016;22(7):648-50

This case series of two pregnant women infected with the Zika virus in Barcelona, Spain and provides an algorithm for diagnosing pregnant women with suspected ZIKV infection in non-endemic areas.


Data sharing – A code of conduct for data on epidemics


Authors: Capua I

Published in: Nature. 2016;16;534(7607):326

This correspondence urges Brazil to speed up reforms to current biosecurity legislation, enabling sharing of vital Zika virus samples and information.

Zika virus outbreak in Haiti in 2014: molecular and clinical data


Authors: Kednicky J, Beau De Rochars VM, El Badry M, et al.

Published in: PLoS Negl Trop Dis. 2016;10(4):e0004687

Background Zika virus (ZIKV), first isolated in Uganda in 1947, is currently spreading rapidly through South America and the Caribbean. In Brazil, infection has been linked with microcephaly and other serious complications,

Zika virus and neurological disease—approaches to the unknown


Authors: Solomon T, Baylis M, Brown D.

Published in: Lancet Infect Dis. 2016;16(4):402-404

This article comments on the origins and consequences of recent Zika virus outbreaks, highlighting the urgent need to address several key gaps in knowledge regarding this virus.

Brazil’s scientists scramble to solve the Zika puzzle


Author: Bispo A

Published in: Bull World Health Organ. 2016;94:165–166

In this interview, Anna Bispo describes the history of Zika virus in Brazil, including its potential links to an increase in microcephaly cases, and describes groundbreaking work in Zika virus diagnostics and virology at the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil.

Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB-HIV EuroCoord study


Authors: Turkova A, Chappell E, Chalermpantmetagul S, et al.

Published in: Int J Tuberc Lung Dis 2016;20(11):1448-1456.

Setting Centres participating in the Paediatric European Network for Treatment of AIDS (PENTA), including Thailand and Brazil.

Objective To describe the incidence, presentation, treatment and treatment outcomes of tuberculosis (TB) in human immunodeficiency virus (HIV) infected children.

Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand


Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.

Published in: Antivir Ther. 2016; 21(4): 353-8

Background Surveillance for mid- and long-term antiretroviral therapy (ART) toxicity in children is important for informing treatment guidelines. We assessed the safety of darunavir (DRV) and atazanavir (ATV), commonly used as second-line protease inhibitors following lopinavir/ritonavir,

Interventions to improve treatment, retention and survival outcomes for adolescents with perinatal HIV-1 in high- and middle-income countries: Moving on up.


Authors: Judd A, Sohn A, Collins J.

Published in: Curr Opin HIV AIDS 2016;11(5):477-486.

Purpose of review There is an increasing number of deaths among adult survivors of perinatal HIV. Multiple and complex factors drive this mortality, including problems with retention in care and adherence during adolescence,

Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project.


Authors: Ngo-Giang-Huong N, Wittkop L, Judd A, et al. For EuroCoord-CHAIN-EPPICC joint project study group.

Published in: BMC Infect Dis. 2016;16(1):654.

Background Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.

Editorial Overview: Virus–vector interactions


Authors: Kramer LD, Long MT

Published in: Curr Opin Virol. 2016 Dec;21:v-vi


Is pregnancy a barrier to the proposed lower dose of efavirenz?


Authors: Schalkwijk S, ter Heine R, Colbers A,  Huitema A, Denti P, Dooley K, Capparelli E, Best B, Cressey T, Greupink R, Russel F, Mirochnick M, Burger D.

Published: 17th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, June 8th-10th 2016, Washington DC.  P_26


Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early


Authors: Colbers A, Schalkwijk S, Konopnicki D, Hawkins D, Hidalgo Tenorio C, Moltò J, Taylor G, Weizsacker K, van der Ende M, Burger D

Published: Oral presentation at 17th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, June 8th-10th 2016, Washington DC


A Comparison of the Pharmacokinetics of Efavirenz During Pregnancy and Postpartum


Authors: Schalkwijk S, Best B, Colbers A, SteK A, Wang  J, Hawkins D, Mirochnick M, Burger D; for the The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1026s Protocol Team, and the Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-infected Pregnant Women (PANNA) Study Network

Published: 23rd Conference on Retroviruses and Opportunistic Infections, February 22nd-25th 2016, Boston


Etravirine Pharmacokinetics in HIV-Infected Pregnant Women


Authors: Blonk MI, Colbers AP, HidalgoTenorio C, et al.

Published inFront Pharmacol. 2016 Aug 4;7:239.

Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women.

Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women.

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman


Authors: Schalkwijk S, Feiterna-Sperling C, Weizsacker K, et al.

Published in: AIDS. 2016; 30(12):1999-2001.

No Abstract available

BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial


Author: Butler K, Inshaw J, Ford D, et al.

Published in:  Health Technol Assess. 2016;20(49):1-108.

Background For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity, better adherence and cost savings.

Objectives To determine whether or not efavirenz (EFV)-based ART in short cycles of 5 days on and 2 days off is as efficacious (in maintaining virological suppression) as continuous EFV-based ART (continuous therapy;

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial


Author: The BREATHER (PENTA 16) Trial Group

Published inLancet HIV. 2016;3(9):e421-430

Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART).

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women


Authors: Schalkwijk S, Colbers A, Konopnicki D, et al. For PANNA network

Published inAIDS. 2016;30(8):1239-44.

Objective To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum.

Design A nonrandomized, open-label, multicentre, phase-IV study.

Methods HIV-positive pregnant women receiving abacavir 600 mg q.d.

High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIVpositive women in Ukraine, but no increased HIV mother-to-child transmission risk


Authors: Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C. Ukraine European Collaborative Study in EuroCoord.

Published in: BMC Pregnancy Childbirth. 2016;27;16:94

Background Over 3500 HIV-positive women give birth annually in Ukraine, a setting with high prevalence of sexually transmitted infections. Herpes simplex virus Type 2 (HSV-2) co-infection may increase HIV mother-to-child transmission (MTCT) risk.

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption


Authors: Ananworanich J, Melvin D, Ramos Amador JT, et al; on behalf of the PENTA 11 study group.

Published in: AIDS. 2016;30(7):1075-81.

Objective Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of life (QoL) are important for managing unplanned interruptions and planned interruptions in HIV cure research.

Design Children previously randomized to continuous (continuous ART, 

First reported use of elvitegravir and cobicistat during pregnancy


Authors: Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D; PANNA network.

Published inAIDS. 2016;30(5):807-8.

Abstract not available

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future


Authors: Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.

Published inEuro Surveill.2016;21(10): 30162

Abstract Accurate ascertainment of the number of children living with human immunodeficiency virus (HIV) is important to plan paediatric and adolescent health services. In Europe, the first generation of perinatally HIV-infected survivors are transferring to adult care and their health needs are unknown.

The European Paediatric Mycology Network (EPMyN): Towards a Better Understanding and Management of Fungal Infections in Children


Author: Warris A; European Paediatric Mycology Network (EPMyN)*.

Published in: Curr Fungal Infect Rep. 2016;10:7-9.

Abstract: The European Paediatric Mycology Network (EPMyN) was launched in 2014 to create a European platform for research and education in the field of paediatric mycology. The EPMyN aims to address the lack of paediatric specific evidence and knowledge needed to (1) improve the management and outcome of invasive fungal infections in children and neonates and to (2) enhance and develop paediatric anti-fungal stewardship programmes.

When information does not suffice: young people living with HIV and communication about ART adherence in the clinic


Authors: S. Bernays, S. Paparini, D. Gibb & J. Seeley

Published in: Vulnerable Child Youth Stud. 2016;11(1):60-68

Abstract Despite mounting evidence recommending disclosure of human immunodeficiency virus (HIV) status to young people with perinatally acquired HIV as a central motivating factor for adherence to antiretroviral therapy, many young people continue to experience disclosure as a partial event,

Darunavir population pharmacokinetics in pregnancy


Authors: Moltò J, Valle M, Colbers A, Clotet V, Burger D.

Published: 16th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26th – 28th 2015, Westin Alexandria